

Table S1. The characteristics of studies included in the systematic review and meta-analysis.

Study [Ref]	Country	Sample size	Age (Mean or Median)	Ovarian Cancer	Diagnostic criteria	Treatment	B7-H4 expression	B7-H4 Method	Outcomes Reported	NOS
Choi IH et al., 2003 [7]	USA	26	NA	Ovarian cancer stage I	FIGO	NA	Protein	IHC- Mabs staining	Proportions	7
Gitto SB et al., 2024 [8]	United Kingdom	12	NA	Primary and recurrent high grade serous ovarian cancer; stage I and IV	FIGO	Cytoreductive surgery	Protein	IHC-flow cytometry	Proportions	5
Guo LX et al., 2016 [9]	China	80	NA	Malignant epithelial ovarian tumor Stage I-IV	FIGO	NA	Protein	IHC	Proportions	7
Hwang C et al., 2023 [10]	South Korea	137	57.9	Ovarian serous carcinoma STAGE-I, II and III	WHO, FIGO and Allred Scoring system	Exploratory laparotomy, optimal debulking surgery, sub optimal debulcking surgery	Protein and mRNA	IHC-tissue microarray, quantitative real time PCR	Proportions	8
Kryczek I et al., 2007 [11]	USA	70	58,53,67,60 for stage I,II,III and IV, respectively	Epithelial Ovarian Carcinoma Staging Stage I-IV	FIGO	Untreated patients	Protein	Mean fluorescent intensity	Proportions, UHR-PFS, AHR-PFS (Adjusted for: Stage and treg cells)	7
Liang L et al., 2016 [12]	USA	306	60	Ovarian serous carcinoma Stage : I-IV	WHO, FIGO system, 4 score grading system of IHC staining	U n d e r w e n t surgery patients	Protein	IHC	Proportions, UHR-PFS, UHR-OS	8
Liao LH et al., 2010 [13]	China	86	NA	Primary epithelial ovarian cancer Stage: I	NA	NA	mRNA and protein	RT-PCR, IHC with PV-6000	Proportions	8
MacGregor HL, et al., 2019 [14]	Canada	25	NA	High grade serous carcinoma Stage: III	NA	Debulking procedure	Protein	Flow cytometry and IHC	Proportions	6
Niu N et al., 2021 [15]	USA	202	NA	High grade serous ovarian carcinoma Stage: IV	RECIST, Advanced TNM staging	Upfront surgery	Protein	Multiplec IHC- Nano String assay	Proportions	8
Salceda S et al., 2005 [16]	USA	13	NA	Papillary serous adenocarcinoma	NA	NA	mRNA and protein	RT-PCR	Proportions	5

Simon I et al., 2007 [17]	USA	251	57.5	Serous, endometroid and clear cell ovary cancer stage I-IV	FIGO	Debulking procedure	Protein	Monoclonal antibody sandwich ELISA	Proportions, UHR-PFS, AHR-PFS (Adjusted for: Stage)	8
Tringler B et al., 2006 [18]	USA	70	55.2	Serous, endometroid and clear cell ovary cancer stage I	WHO, tumor grade criteria	NA	Protein	IHC,Western Blot	Proportions	6
Wang L et al., 2016 [19]	China	67	NA	Ovarian serous carcinoma Stage :I-IV	Youden Index , pathological grading, lymph node metastasis of ovarian cancer, FIGO stage FIGO	Surgical treatment	Protein	Elivsion TM IHC staining method	Proportions, UHR-PFS	6
Xu M et al., 2016 [20]	China	112	55.1	Epithelial Ovarian Carcinoma Stage I-IV		Post operative lifetime	Protein	Mouse-rabbit EnVison detection	Proportions, UHR-PFS	7
Zhang LL et al., 2010 [21]	China	40	48	Epithelial Ovarian Carcinoma Stage I-IV	FIGO	NA	Protein	Elivsion TM IHC staining method	Proportions	6
Zheng C, Yang R. 2019 [22]	China	50	NA	Ovarian cancer tissue Stage: I-IV	WHO classification	NA	Protein	Immuno histochemical streptavidin-peroxidase (SP) method	Proportions	6
Zheng Y et al., 2007 [23]	USA	259	57	Primary epithelial ovarian cancer Stage I-IV	FIGO,WHO criteria,	Surgery followed by platinum based chemotherapy	Protein	Sandwich type ELISA	UHR-PFS, AHR-PFS (Adjusted for: Clinical variables and markers) AHR-PFS (Adjusted for: Age)	8
Anderson GL et al., 2010 [24]	USA	34	59	Ovarian cancer Stage: I A-IV C	FIGO	NA	Protein	ELISA		6

Oikonomopoulou K et al., 2008 [25]	Canada	98	50	Ovarian carcinoma I-IV	FIGO,WHO criteria	Chemotherapy	Protein	Sandwich ELISA	UHR-PFS, AHR-PFS, UHR-OS, AHR-OS (Adjusted for: age, stage and response to chemotherapy)	7
------------------------------------	--------	----	----	------------------------	-------------------	--------------	---------	----------------	--	---

AHR-OS: Adjusted hazard ratio – Overall survival, AHR-PFS: Adjusted hazard ratio – Progression free survival, ELISA: Enzyme-Linked Immunosorbent Assay, FIGO: International Federation of Gynaecology and Obstetrics, IHC: Immunohistochemistry, mRNA: messenger Ribonucleic Acid, PCR: Polymerase Chain Reaction, PV-6000: Photovoltaic-6000, RECIST: Response Evaluation Criteria in Solid Tumours, RT-PCR: Reverse Transcription Polymerase Chain Reaction, TNM staging: Tumour, Node, Metastasis staging, UHR-OS: Unadjusted hazard ratio – Overall survival, UHR-PFS: Unadjusted hazard ratio – Progression free survival, USA: United States of America, WHO: World Health Organization